medigraphic.com
ISSN 1405-1710 (Print)

2017, Number 2

<< Back Next >>

Rev Cent Dermatol Pascua 2017; 26 (2)

Extranodal lymphoma of nasal type T/NK cells. Presentation of a clinical case

Vega-González MTJ, Avilés-Salas A, Pérez-Martínez R, Orozco-Anahuati AP

Language: Spanish
References: 21
Page: 54-59
PDF size: 358.59 Kb.


ABSTRACT

Primary cutaneous lymphomas are the second most common site of involvement of extranodal non-Hodgkin lymphoma. The nasal type lymphoma is considered a T/NK cutaneous lymphoma by the 2005 WHO/EORTC classification. Although in USA and Western it is not considered a common malignancy, in Central and South America, especially Mexico and Peru, a high incidence has been reported. The disease affects primarily the nasal and pharyngeal regions but chest and limbs can also be affected. This is an aggressive neoplasm; if we don’t have a high index of suspicion, diagnosis will be delayed. Unfortunately, the response to therapy is poor. We present the case of a 25 year-old male patient with an ulcerated tumor on the left nasal, eyelid and malar regions. After two skin biopsies and a clinic and histopathological correlation, the diagnosis of extranodal T/NK lymphoma nasal type was confirmed. Despite chemotherapy and radiotherapy the disease progressed and the patient died eight months after diagnosis.


REFERENCES

  1. Connors J, Hsi E, Foss F. Lymphoma of the skin. Hematology Am Soc Hematol Educ Program. 2002; 1: 263-282.

  2. Willemze R, Jaffe E, Burg G, Cerroni L, Berti E, Swerdlow SH et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105: 3768-3785.

  3. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S et al. EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study group of the european organization for research and treatment of cancer. Blood. 1997; 90: 354-371.

  4. Jaffe ES, Harris NL, Stein H, Vardiman JW et al. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. pp. 204-207.

  5. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3,884 cases. Blood. 2009; 113: 5064-5073.

  6. Dores GM, Anderson WF, Devesa SS. Cutaneous lymphomas reported to the National Cancer Institute’s surveillance, epidemiology, and end results program: applying the new WHO-European Organization for Research and Treatment of Cancer classification system. J Clin Oncol. 2005; 23: 7246-7248.

  7. Yasukawa K, Kato N, Kodama K, Hamasaka A, Hata H. The spectrum of cutaneous lymphomas in Japan: a study of 62 cases based on the World Health Organization Classification. J Cutan Pathol. 2006; 33: 487-491.

  8. Han JH, Ko YH, Kang YK, Kim WS, Kim YJ, Kim I et al. Characteristics of cutaneous lymphomas in Korea according to the new WHO-EORTC classification: report of a nationwide study. Korean J Pathol. 2014; 48: 126-132.

  9. Liao JB, Chuang SS, Chen HC, Tseng HH, Wang JS, Hsieh PP. Clinicopathologic analysis of cutaneous lymphoma in Taiwan: a high frequency of extranodal natural killer/t-cell lymphoma, nasal type, with an extremely poor prognosis. Arch Pathol Lab Med. 2010; 134: 996-1002.

  10. Dummer R, Willers J, Kamarashev J, Urosevic M, Döbbeling U, Burg G. Pathogenesis of cutaneous lymphomas. Semin Cutan Med Surg. 2000; 19: 78-86.

  11. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol. 2007; 38: 1293-1304.

  12. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005; 19: 2186-2194.

  13. Sosa Durán E. Linfoma Nasal de células T/NK: características epidemiológicas y clínicas. Experiencia en el Servicio de Oncología del Hospital Juárez de México. México, UNAM-Tesis de subespecialidad. 2011. p. 6.

  14. Siu LL, Chan JK, Kwon YL. Natural killer cell malignancies: clinicopathological and molecular features. Histol Histopathol. 2002; 17: 539-554.

  15. Campbell SM, Peter SB, Zirwas MJ, Wong HK. Immunophenotypic diagnosis of primary cutaneous lymphomas: a review for the practicing dermatologist. J Clin Aesthet Dermatol. 2010; 3: 21-25.

  16. Yu JB, Zuo Z, Zhang WY, Yang QP, Zhang YC, Tang Y et al. Identification of immunophenotypic subtypes with different prognoses in extranodal natural killer/T-cell lymphoma, nasal type. Human Pathol. 2014; 45: 2255-2262.

  17. Yang Y, Zhang YJ, Zhu Y, Cao JZ, Yuan ZY, Xu LM et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study. Leukemia. 2015; 29: 1571-1577.

  18. Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, Harabuchi Y et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and Peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011; 118: 6018-6022.

  19. Yamazaki E, Tomita N, Koyama S. Serum ferritin level is prognostic of patient outcome in extranodal NK/T cell lymphoma, nasal type. Medical Oncology. 2014; 31: 149.

  20. Chaudhary RK, Bhatt VR, Vose JM. Management of extranodal natural killer/t-cell lymphoma, nasal type. Clin lymphoma Myeloma Leuk. 2015; 15: 245-252.

  21. Kim SJ, Oh SY, Hong JY, Chang MH, Lee DH, Huh J et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol. 2010; 21: 1058-1063.




2020     |     www.medigraphic.com